Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 701–800 of 1,031
Li, B., Liu, J., Jia, Y., Wang, J., Xu, Z., Qin, T., Shi, Z., Song, Z., Peng, S., Huang, H., et al. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22510 · Cited by 72
Nutritional Regulation of Intestinal Stem Cells
Alonso, S., & Yilmaz, Ö. H. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051644 · Cited by 73
Synonymous mutations reveal genome-wide levels of positive selection in healthy tissues
Poon, G. Y. P., Watson, C. J., Fisher, D. S., & Blundell, J. R. (2021) · Nature Genetics · doi:10.1038/s41588-021-00957-1 · Cited by 65
Recent advances in understanding clonal haematopoiesis in aplastic anaemia
Stanley, N. L., Olson, T. S., & Babushok, D. V. (2017) · British Journal of Haematology · doi:10.1111/bjh.14510 · Cited by 67
Clonal hematopoiesis as a model for premalignant changes during aging
Steensma, D. P., & Ebert, B. L. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.001 · Cited by 65
Clonal hematopoiesis in cancer
Park, S. J., & Bejar, R. L. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.02.001 · Cited by 74
Midic, D., Rinke, J., Perner, F., Müller, V., Hinze, A., Pester, F., Landschulze, J., Ernst, J., Gruhn, B., Matziolis, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0869-y · Cited by 63
Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
Burchert, A. (2021) · Haematologica · doi:10.3324/haematol.2019.240747 · Cited by 68
Interleukin-1 (IL-1) and the inflammasome in cancer
Prêtre, V., Papadopoulos, D., Regard, J. B., Pelletier, M. R., & Woo, J. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155850 · Cited by 70
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock
Scolari, F. L., Abelson, S., Brahmbhatt, D. H., Medeiros, J. J. F., Fan, C. S., Fung, N. L., Mihajlovic, V., Anker, M. S., Otsuki, M., Lawler, P. R., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2588 · Cited by 66
Functional diversity of cardiac macrophages in health and disease
Yang, S. H., Penna, V. R., & Lavine, K. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01109-8 · Cited by 73
The curious origins of angioimmunoblastic T-cell lymphoma
Cortés, J. R., & Palomero, T. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000261 · Cited by 64
Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Heuser, M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.24 · Cited by 71
Gondek, L. P., & DeZern, A. E. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30211-x · Cited by 63
“3 The diagnosis of some types of acute myeloid leukaemia with recurrent cytogenetic abnormalities—such as inv(16), t(8;21), or t(15;17)—can now be made without referring to the blast count.”
BackgroundHigh prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers
Guermouche, H., Ravalet, N., Gallay, N., Deswarte, C., Foucault, A., Beaud, J., Rault, E., Saindoy, E., Lachot, S., Martignoles, J.-A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001582 · Cited by 63
“CHIP has been described as a risk factor for blood cancer.(5,8) However, the diagnosis of most blood cancers relies on morphologic and genetic examination of the bone marrow (BM), and CH has never been evaluated in BM samples from healthy individuals.”
BackgroundPastoret, C., Desmots, F., Drillet, G., Le Gallou, S., Boulland, M.-L., Thannberger, A., Doncker, A.-V., Salaun, V., Damaj, G. L., Veyrat-Masson, R., et al. (2021) · Blood · doi:10.1182/blood.2020006721 · Cited by 63
The Role of Additional Sex Combs-Like Proteins in Cancer
Micol, J., & Abdel-Wahab, O. I. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026526 · Cited by 67
“Consistent with this, ASXL1 mutations have been repeatedly identified in individuals with clonal hematopoiesis of indeterminate potential, a condition whose frequency increases with advanced age (Genovese et al. 2014; Jaiswal et al. 2014; Xie et al. 2014).”
BackgroundThe Molecular Genetics of Myeloproliferative Neoplasms
Marneth, A. E., & Mullally, A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034876 · Cited by 69
“Truncating and frameshift PPM1Dmutations in exon 6 have been found in clonal hematopoiesis, MDS, andMPNs (Genovese et al. 2014; Xie et al. 2014; Coombs et al. 2017; Lindsley et al. 2017).”
BackgroundWeber, S., van der Leest, P., Donker, H. C., Schlange, T., Timens, W., Tamminga, M., Hasenleithner, S. O., Graf, R., Moser, T., Spiegl, B., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00182 · Cited by 68
“9%) were also detected in PBMCs (Fig 2A), whereas most CH-related variants were identified in TP53 (Fig 2B).(19,27,28) The number and presence of CHrelated variants were associated with higher age (Fig 2C and Data Supplement).”
BackgroundThe Mechanism of Stem Cell Aging
Mi, L., Hu, J., Li, N., Gao, J., Huo, R., Peng, X., Zhang, N., Liu, Y., Zhao, H., Liu, R., et al. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10317-5 · Cited by 62
Groarke, E. M., Patel, B. A., Shalhoub, R. N., Gutierrez‐Rodrigues, F., Desai, P. A., Leuva, H., Zaimoku, Y., Paton, C., Spitofsky, N., Lotter, J., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01636-8 · Cited by 71
“Older age is associated with increased rates of both CH, and myeloid neoplasia, independent of an AA diagnosis [36, 37].”
BackgroundKestenbaum, B. R., Bick, A. G., Vlasschaert, C., Rauh, M. J., Lanktree, M. B., Franceschini, N., Shoemaker, M. B., Harris, R. C., Psaty, B. M., Köttgen, A., et al. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.08.014 · Cited by 66
“36)d No 11,002 3 [3-4] 8 [7-15] 2,041 1.”
BackgroundInfluentialBond, J., Touzart, A., Leprêtre, S., Graux, C., Bargetzi, M., Lhermitte, L., Hypolite, G., Leguay, T., Hicheri, Y., Guillerm, G., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.197848 · Cited by 60
ASXL1 mutation in clonal hematopoiesis
Fujino, T., & Kitamura, T. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.002 · Cited by 72
Dasari, A. N., Grothey, A. F., & Kopetz, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9032 · Cited by 68
Clonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis
Natarajan, P., Jaiswal, S., & Kathiresan, S. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.001926 · Cited by 63
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes
Brunner, A. M., Blonquist, T. M., Hobbs, G. S., Amrein, P. C., Neuberg, D. S., Steensma, D. P., Abel, G. A., & Fathi, A. T. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010165 · Cited by 63
Ghannam, J. Y., Xu, X., Maric, I., Dillon, L., Li, Y., Hsieh, M., Hourigan, C. S., & Fitzhugh, C. D. (2020) · Blood · doi:10.1182/blood.2019004001 · Cited by 8
Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias
Olson, T. L., Cheon, H., Xing, J. C., Olson, K. C., Paila, U., Hamele, C. E., Neelamraju, Y., Shemo, B. C., Schmachtenberg, M., Sundararaman, S. K., et al. (2021) · Blood · doi:10.1182/blood.2020005831 · Cited by 65
Risk prediction for clonal cytopenia: multicenter real-world evidence
Xie, Z., Komrokji, R. S., Al‐Ali, N., Regelson, A., Geyer, S. M., Patel, A. A., Saygin, C., Zeidan, A. M., Bewersdorf, J. P., Mendez, L., et al. (2024) · Blood · doi:10.1182/blood.2024024756 · Cited by 79
Stem Cell-Specific Mechanisms Ensure Genomic Fidelity within HSCs and upon Aging of HSCs
Moehrle, B. M., Nattamai, K., Brown, A., Florian, M. C., Ryan, M., Vogel, M., Bliederhaeuser, C., Soller, K., Prows, D. R., Abdollahi, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.030 · Cited by 59
de Andrade, K. C., Mirabello, L. J., Stewart, D. R., Karlins, E., Koster, R., Wang, M., Gapstur, S. M., Gaudet, M. M., Freedman, N. D., Landi, M. T., et al. (2017) · Human Mutation · doi:10.1002/humu.23320 · Cited by 70
“In this context, the FLOSSIES and the WES Controls databases would be particularly prone as the prevalence of clonal hematopoiesis has a significant increase after the sixth decade of life (Genovese et al., 2014; Jaiswal et al., 2014).”
MethodAge-related clonal haemopoiesis is associated with increased epigenetic age
Robertson, N. A., Hillary, R. F., McCartney, D. L., Terradas-Terradas, M., Higham, J., Sproul, D., Deary, I. J., Kirschner, K., Marioni, R. E., & Chandra, T. (2019) · Current Biology · doi:10.1016/j.cub.2019.07.011 · Cited by 56
Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., Feng, J., Wang, P. P.-S., Babic, M., Parker, W. T., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0479-8 · Cited by 62
Clonal Hematopoiesis: From Mechanisms to Clinical Intervention
Köhnke, T., & Majeti, R. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0901 · Cited by 67
Clonal hematopoiesis and hematological malignancy
Dunn, W. G., McLoughlin, M. A., & Vassiliou, G. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180065 · Cited by 61
Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
Eriksson, A., Lennartsson, A., & Lehmann, S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.009 · Cited by 73
“Even more recently, several publications have reported mutations regarded as drivers in hematologic malignancies to occur in hematologically healthy individuals [122–124].”
BackgroundInfluentialSelf-citationDysregulation of TET2 in hematologic malignancies
Chiba, S. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2122-z · Cited by 70
“The concept of clonal hematopoiesis was established by three recent studies using cohorts of dementia [22], Fig.”
MethodWnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators
Kahn, M. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.007 · Cited by 68
Clonal Hematopoiesis Before, During, and After Human Spaceflight
Mencia-Trinchant, N., MacKay, M. J., Chin, C. R., Afshinnekoo, E., Foox, J., Meydan, C., Butler, D., Mozsary, C., Vernice, N. A., Darby, C. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108458 · Cited by 68
“While the majority of these mutations are neutral and do not favor cell expansion (Busque et al., 1996; Genovese et al., 2014; Jaiswal et al., 2014; Jan et al., 2012; Martincorena et al., 2015), certain mutations can cause cells to gain a growth advantage.”
BackgroundNguyen, Y. T. M., Fujisawa, M., Nguyen, T. B., Suehara, Y., Sakamoto, T., Matsuoka, R., Abe, Y., Fukumoto, K., Hattori, K., Noguchi, M., et al. (2021) · Cancer Science · doi:10.1111/cas.15165 · Cited by 65
Genome Instability and DNA Repair in Somatic and Reproductive Aging
Panier, S., Wang, S., & Schumacher, B. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051122-093128 · Cited by 71
Smeets, M. F. M. A., Tan, S. Y., Xu, J. J., Anande, G., Unnikrishnan, A., Chalk, A. M., Taylor, S., Pimanda, J. E., Wall, M., Purton, L. E., et al. (2018) · Blood · doi:10.1182/blood-2018-04-845602 · Cited by 65
Ortmann, C. A., Dorsheimer, L., Abou-El-Ardat, K., Hoffrichter, J., Assmus, B., Bonig, H., Scholz, A., Pfeifer, H., Martin, H., Schmid, T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.064 · Cited by 60
Acute Myeloid Leukemia: Aging and Epigenetics
Zjablovskaja, P., & Florian, M. C. (2019) · Cancers · doi:10.3390/cancers12010103 · Cited by 69
“These genes are epigenetic regulators which have previously been reported to be involved in MDS and AML development [79,80].”
BackgroundInfluentialMacrophages Orchestrate Hematopoietic Programs and Regulate HSC Function During Inflammatory Stress
Seyfried, A. N., Maloney, J., & MacNamara, K. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01499 · Cited by 68
“Myelodysplastic syndromes (MDS) are a heterogeneous collection of bone marrow failure diseases characterized by cytopenias, marrow dysplasia, and the expansion of mutationcarrying clones (168, 169).”
BackgroundBig Bang Tumor Growth and Clonal Evolution
Sun, R., Hu, Z., & Curtis, C. N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028381 · Cited by 64
“For example, clonal hematopoiesis is relatively common, occurring in 10% of individuals over age 65 and is a strong risk factor for subsequent hematologic cancer (Genovese et al. 2014).”
BackgroundClonal dynamics after allogeneic haematopoietic cell transplantation
Spencer Chapman, M., Wilk, C. M., Boettcher, S., Mitchell, E., Dawson, K., Williams, N., Müller, J., Kovtonyuk, L., Jung, H., Caiado, F., et al. (2024) · Nature · doi:10.1038/s41586-024-08128-y · Cited by 60
Selective and Sensitive Detection of Methylcytosine by Aerolysin Nanopore under Serum Condition
Yu, J., Cao, C., & Long, Y. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b03133 · Cited by 60
The Clinical Management of Clonal Hematopoiesis
Bolton, K. L., Zehir, A., Ptashkin, R. N., Patel, M. A., Gupta, D., Sidlow, R., Papaemmanuil, E., Berger, M. F., & Levine, R. L. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.006 · Cited by 64
Balancing DNA repair to prevent ageing and cancer
Stead, E. R., & Bjedov, I. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112679 · Cited by 73
Arends, C. M., Dimitriou, S., Stahler, A., Hablesreiter, R., Strzelecka, P. M., Stein, C. M., Tilgner, M., Saiki, R., Ogawa, S., Bullinger, L., et al. (2021) · Blood · doi:10.1182/blood.2021014108 · Cited by 64
Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations
Arguelles, O. C., Schöffel, A. C., Capo‐Chichi, J., Abdel-Qadir, H. M., Schuh, A. C., Estrada, M. C., Liu, S., Gupta, V. K., Schimmer, A. D., Yee, K. W. L., et al. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.11.008 · Cited by 64
“TRANSLATIONAL OUTLOOK: The routine use of NGS in patients with hematologic neoplasms may allow the identification of patients at high risk for CVD by identifying somatic genetic mutations described in patients with CHIP.”
BackgroundInfluentialTopological indices of novel drugs used in blood cancer treatment and its QSPR modeling
Nasir, S., Awan, N. U. H., Farooq, F. B., & Parveen, S. (2022) · AIMS Mathematics · doi:10.3934/math.2022660 · Cited by 60
Nakauchi, Y., Azizi, A., Thomas, D., Corces, M. R., Reinisch, A., Sharma, R., Cruz Hernandez, D., Köhnke, T., Karigane, D., Fan, A., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0143 · Cited by 58
Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study
Ahn, H., An, H. Y., Ryu, G., Lim, J., Sun, C.-H., Song, H., Choi, S., Lee, H., Maurer, T. M., Nachun, D. C., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad869 · Cited by 66
Singh, J., Li, N., Ashrafi, E., Thảo, L. T. P., Curtis, D. J., Wood, E. M., & McQuilten, Z. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013228 · Cited by 67
“5 6-8 The most frequent genes mutated were those known to be involved in myeloid blood cancers; however, only a minority of individuals develop blood cancers, leading to the term clonal hematopoiesis of indeterminate potential (CHIP).”
BackgroundInfluentialEckstein, O. S., Wang, L., Punia, J. N., Kornblau, S. M., Andreeff, M., Wheeler, D. A., Goodell, M. A., & Rau, R. E. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.003 · Cited by 62
Coffee, B. W., Cox, H. C., Kidd, J., Sizemore, S., Brown, K. L., Manley, S., & Mancini‐DiNardo, D. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.01.002 · Cited by 60
Coexisting and cooperating mutations in NPM1 -mutated acute myeloid leukemia
Patel, J. L., Schumacher, J. A., Frizzell, K., Sorrells, S., Shen, W., Clayton, A. L., Jattani, R. P., & Kelley, T. W. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.01.027 · Cited by 62
Transcription factor mutations as a cause of familial myeloid neoplasms
Churpek, J. E., & Bresnick, E. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120854 · Cited by 63
Levine, R. L., & Valk, P. J. M. (2019) · Haematologica · doi:10.3324/haematol.2018.205955 · Cited by 60
“Besides acquired mutations in DTA, other well-known pathogenic mutations such as those in TP53, PPM1D, JAK2, CBL, SRSF2 and SF3B1 are involved in clonal hematopoiesis, however, at lower incidence.(17,18) In fact, many of these mutations also persist in complete remission with high variant allele frequencies.”
BackgroundRodríguez, B. J., Córdoba, G. D., Aranda, A. G., Álvarez, M., Vicioso, L., Pérez, C. L., Hernándo, C., Bermejo, B., Julve, A., Lluch, A. M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081183 · Cited by 60
“Regarding clonal hematopoiesis, detectable clonal expansions most frequently involved somatic mutations in DNMT3A, ASXL1, and TET2 genes [40].”
BackgroundGenomic Instability of iPSCs and Challenges in Their Clinical Applications
Yoshihara, M., Oguchi, A., & Murakawa, Y. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-31206-0_2 · Cited by 60
Muto, T., Guillamot, M., Yeung, J., Fang, J., Bennett, J. R., Nadorp, B., Lasry, A., Zea-Redondo, L., Choi, K., Gong, Y., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2021.12.007 · Cited by 62
“Moreover, CHIP mutations are a strong risk factor for subsequent hematologic cancer(Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).”
Kennedy, S. R., Zhang, Y., & Risques, R. A. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.007 · Cited by 65
“However, the absolute risk is still only ~1% per year [11], indicating that in the vast majority of cases the clones never result in malignancy.”
BackgroundHand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis
SanMiguel, J. M., Young, K., & Trowbridge, J. J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.197 · Cited by 57
NPM 1 Mutations in AML—The Landscape in 2023
Sharma, N., & Liesveld, J. L. (2023) · Cancers · doi:10.3390/cancers15041177 · Cited by 67
“DNMT3A, found increasingly in aging populations without overt leukemia [28], is a driver gene which precedes NMP1mut, providing a self-renewal advantage to the leukemic clones.”
BackgroundNakamura, Y., Tsukada, Y., Matsuhashi, N., Murano, T., Shiozawa, M., Takahashi, Y., Oki, E., Goto, M., Kagawa, Y., Kanazawa, A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1651 · Cited by 69
DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders
Sato, H., Wheat, J. C., Steidl, U. G., & Ito, K. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00187 · Cited by 64
“Two whole-exome sequencing studies of peripheral blood mononuclear cells longitudinally tracked clonal hematopoiesis during aging to establish whether the presence of clonal hematopoiesis correlated with AML development (5, 27).”
BackgroundAcuña‐Hidalgo, R., Deriziotis, P., Steehouwer, M., Gilissen, C., Graham, S. A., van Dam, S., Hoover-Fong, J. E., Telegrafi, A. B., Destrèe, A., Śmigiel, R. S., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006683 · Cited by 65
McKerrell, T., Park, N., Chi, J., Collord, G., Moreno, T., Ponstingl, H., Dias, J., Gerasimou, P., Melanthiou, K., Prokopiou, C., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007047 · Cited by 59
Chang, C.-J., Kotini, A. G., Olszewska, M., Georgomanoli, M., Teruya‐Feldstein, J., Sperber, H., Sánchez, R., DeVita, R. J., Martins, T. J., Abdel-Wahab, O. I., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.03.020 · Cited by 61
High Detection Rate of MYD88 Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas
Watanabe, J., Natsumeda, M., Okada, M., Kobayashi, D., Kanemaru, Y., Tsukamoto, Y., Oishi, M., Kakita, A., & Fujii, Y. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00308 · Cited by 58
Immune Aging in Rheumatoid Arthritis
Weyand, C. M., & Goronzy, J. J. (2025) · Arthritis & Rheumatology · doi:10.1002/art.43105 · Cited by 67
“84 CHIP incidence is closely correlated with age and is present in <1% of individuals <40 years old and in 10% to 20% of individuals >70 years old.”
Kato, M., Yamashita, T., Suzuki, R., Matsumoto, K., Nishimori, H., Takahashi, S., Iwato, K., Nakaseko, C., Kondo, T., Imada, K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.23 · Cited by 58
Li, S. D., Ma, M., Li, H., Waluszko, A., Sidorenko, T., Schadt, E. E., Zhang, D. Y., Chen, R., & Ye, F. (2017) · Genome Medicine · doi:10.1186/s13073-017-0478-1 · Cited by 69
Myeloproliferative neoplasms: from origins to outcomes
Nangalia, J., & Green, A. R. (2017) · Hematology · doi:10.1182/asheducation-2017.1.470 · Cited by 69
“Third, no known oncogenic drivers can be identified from analysis of whole-exome or wholegenome sequencing in up to half of individuals with CH, suggesting that oncogene-independent mechanisms, such as clonal drift or reduced bone marrow genetic diversity, can lead to clonal expansion.(86,88) It is recognized that HSC…”
BackgroundNagy, A., Bhaduri, A., Shahmarvand, N., Shahryari, J., Zehnder, J. L., Warnke, R. A., Mughal, T. I., Ali, S. M., & Ohgami, R. S. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017009654 · Cited by 62
“30 000 individuals.(27,28) The only instance of this mutation identified to date, to our knowledge, has been in a case of AML as mentioned in the previous paragraph.”
BackgroundGrabek, J., Straube, J., Bywater, M., & Lane, S. W. (2020) · Cells · doi:10.3390/cells9081901 · Cited by 53
“DNMT3A mutations are the most common mutation identified in clonal haematopoiesis [114,115].”
BackgroundBrain Somatic Mutation in Aging and Alzheimer's Disease
Miller, M. B., Reed, H. C., & Walsh, C. A. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-121520-081242 · Cited by 58
“Whereas limited studies have so far not revealed BRAF V600E mutations in AD brain (58, 93), small numbers of cases show mutations in DNMT3A or TET2, which are cancer-associated genes that are also mutated in clonal hematopoiesis (44, 54), or in the PI3K, MAPK, or AMPK pathways, whose significance must be evaluated thr…”
BackgroundPellagatti, A., Roy, S., Di Genua, C., Burns, A., McGraw, K., Valletta, S., Larrayoz, M. J., Fernandez-Mercado, M., Mason, J., Killick, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.129 · Cited by 57
Detection of structural mosaicism from targeted and whole-genome sequencing data
King, D. A., Sifrim, A., Fitzgerald, T. W., Rahbari, R., Hobson, E., Homfray, T., Mansour, S., Mehta, S. G., Shehla, M., Tomkins, S. E., et al. (2017) · Genome Research · doi:10.1101/gr.212373.116 · Cited by 59
Mutational signatures and mutable motifs in cancer genomes
Rogozin, I. B., Pavlov, Y. I., Goncearenco, A., De, S., Lada, A. G., Poliakov, E., Panchenko, A. R., & Cooper, D. N. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx049 · Cited by 58
“For instance, clonal hematopoiesis is often characterized by DNMT3A and TET2 mutations [64, 74].”
In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions
Scala, S., & Aiuti, A. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000039 · Cited by 48
“3000 somatic mutations of unusual allelic fractions on peripheral blood samples collected from 12380 individuals, it was assessed that 10% of subjects older than 65 years old showed clonal hematopoiesis.(67) This phenomenon is increasingly common as people age and is associated with a higher risk of developing hematol…”
BackgroundBroeders, W., Bekkering, S., Messaoudi, S. E., Joosten, L. A. B., van Royen, N., & Riksen, N. P. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00935-6 · Cited by 63
“CH is associated with an augmented all-cause mortality risk [53, 63] and an increased risk of atherosclerotic CVD [49, 64].”
BackgroundSchönfeld, L., Rinke, J., Hinze, A., Nagel, S. N., Schäfer, V., Schenk, T., Fabisch, C., Brümmendorf, T. H., Burchert, A., le Coutre, P., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01648-4 · Cited by 57
“Age-related clonal hematopoiesis is associated with an increased risk of developing hematologic cancer [11].”
BackgroundInfluentialHematopoietic Stem Cells and the Immune System in Development and Aging
Shevyrev, D., Tereshchenko, V., Berezina, T. N., & Александрович, Р. С. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065862 · Cited by 66
New data shed light on Y‐loss‐related pathogenesis in myelodysplastic syndromes
Ganster, C., Kämpfe, D., Jung, K., Braulke, F., Shirneshan, K., Machherndl‐Spandl, S., Suessner, S., Bramlage, C. P., Legler, T. J., Koziolek, M. J., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22282 · Cited by 57
SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort
Tlemsani, C., Luscan, A., Leulliot, N., Bieth, É., Afenjar, A., Baujat, G., Doco‐Fenzy, M., Goldenberg, A., Lacombe, D., Lambert, L., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103638 · Cited by 61
Flotho, C., Sommer, S., & Lübbert, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.011 · Cited by 63
The role of JAK2 inhibitors in MPNs 7 years after approval
Passamonti, F., & Maffioli, M. (2018) · Blood · doi:10.1182/blood-2018-01-791491 · Cited by 60
Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia
Ernst, T., Busch, M., Rinke, J., Ernst, J., Haferlach, C., Beck, J. F., Hochhaus, A., & Gruhn, B. (2018) · Leukemia · doi:10.1038/s41375-018-0157-2 · Cited by 58
Boucai, L., Falcone, J., Ukena, J., Coombs, C. C., Zehir, A., Ptashkin, R. N., Berger, M. F., Levine, R. L., & Fagin, J. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00803 · Cited by 59
“Papillary thyroid cancer 115 (37) 46/115 (40) 6/115 (5) Poorly differentiated thyroid cancer 87 (28) 37/87 (43) 5/87 (6) Anaplastic thyroid cancer 47 (15) 15/47 (32) 2/47 (4) Hurthle cell carcinoma 26 (9) 8/26 (31) 2/26 (8) Medullary thyroid cancer 30 (10) 7/30 (23) 1/30 (3) Follicular thyroid cancer 4 (1) 2/4 (50) 0/…”
BackgroundPlasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma
Bacon, J. V. W., Annala, M., Soleimani, M., Lavoie, J., So, A., Gleave, M. E., Fazli, L., Wang, G., Chi, K. N., Kollmannsberger, C., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.12.018 · Cited by 60
The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors
Rinaldi, J., Sokol, E. S., Hartmaier, R. J., Trabucco, S. E., Frampton, G. M., Goldberg, M. E., Albacker, L. A., Daemen, A., & Manning, G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231999 · Cited by 65
“Clonal hematopoiesis is observed in 10% of adults over 65 years of age, but in only 1% of those under 50, and has been associated with cancer [65,72].”
BackgroundThe DNA methylation landscape of hematological malignancies: an update
Blecua, P., Martinez‐Verbo, L., & Esteller, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12744 · Cited by 59
What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms
Voso, M. T., Falconi, G., & Fabiani, E. (2021) · Blood · doi:10.1182/blood.2021010764 · Cited by 61
Lodato, M. A., & Walsh, C. A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz191 · Cited by 56
“However, C>T mutations are generally abundant in post-zygotic mutations discovered by non-WGA-based analyses of mutations in various tissues, for example the blood (57,58), skin (59), male reproductive tract (60), digestive tract (43,61) and liver (43), suggesting that C>T variants likely play a prominent role in shap…”
Background‘CHIP’ping away at clonal hematopoiesis
Link, D. C., & Walter, M. J. (2016) · Leukemia · doi:10.1038/leu.2016.130 · Cited by 58
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.